GlassScriptPhysician profile
Carlos Obregon
NPI 1093785487
$11,933.53
in general payments reported to CMS, 2019-2025
41 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $1,410 · 2021: $1,642 · 2022: $1,829 · 2023: $1,686 · 2024: $2,395 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,889 · Travel and Lodging: $803 · Education: $50.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,888.95 |
| Travel and Lodging | $802.97 |
| Education | $50.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,347.00 | 2019-2025 | Tezspire, Fasenra, Symbicort |
| Glaxosmithkline, LLC. | $1,344.80 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $992.19 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $980.05 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $870.77 | 2019-2025 | Dupixent |
| Intuitive Surgical, INC. | $868.26 | 2024 | |
| Insmed, INC. | $476.40 | 2019-2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $369.28 | 2019-2025 | |
| Genentech USA, INC. | $347.42 | 2019-2025 | Xolair |
| Amgen INC. | $345.23 | 2021-2025 | Tezspire |
| United Therapeutics Corporation | $300.16 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Bayer Healthcare Pharmaceuticals INC. | $253.10 | 2019-2023 | |
| Grifols USA, LLC | $236.35 | 2019-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $211.07 | 2020-2025 | Wakix |
| Sunovion Pharmaceuticals INC. | $191.28 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Obregon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.